All Trials

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-refractory recurrent/metastatic HNSCC (oral cavity, oropharynx, larynx, hypopharynx), PD-L1 CPS ≥1, ECOG 0–2, and no prior systemic therapy for R/M disease are randomized to pembrolizumab alone vs pembrolizumab plus cetuximab. Pembrolizumab is an anti–PD-1 antibody; cetuximab is an anti-EGFR antibody, with the combination tested to enhance efficacy in this setting.

ClinicalTrials.gov ID: NCT06589804

A Phase II Trial of Lovastatin and Pembrolizumab in Patients with RM HNSCC (LAPP)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma (ECOG 0–1) not candidates for salvage surgery receive pembrolizumab plus oral lovastatin; prior checkpoint inhibitor use and current statin therapy are excluded. Pembrolizumab is an anti–PD-1 antibody, and lovastatin (HMG‑CoA reductase inhibitor) is added to potentially enhance antitumor immunity via mevalonate pathway inhibition.

ClinicalTrials.gov ID: NCT06636734

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic nasopharyngeal carcinoma after platinum–gemcitabine and prior PD‑1/L1 therapy (up to two prior lines; ECOG 0–2; treated/stable brain mets allowed) are randomized to nivolumab (PD‑1) plus ipilimumab (CTLA‑4) with or without cabozantinib, a multikinase inhibitor of MET/VEGFR2/AXL. Aims to determine whether adding cabozantinib improves outcomes versus dual checkpoint blockade alone.

ClinicalTrials.gov ID: NCT05904080

Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or metastatic nasopharyngeal carcinoma, systemic treatment–naïve for the metastatic setting and with measurable disease, receive induction gemcitabine/platinum plus toripalimab (anti–PD-1), with optional switch to carboplatin from cycle 2, followed by maintenance toripalimab. Excludes candidates for curative local therapy, prior systemic therapy for R/M disease, early recurrence after chemoradiation (<6 months), rapidly progressive disease, and active/untreated CNS metastases.

ClinicalTrials.gov ID: NCT06457503

A Randomized Phase III TriaL Comparing SingLe- Versus Multi-Fraction Spine STereotActic Radiosurgery for Patients With Spinal Metastases (ALL-STAR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic disease to 1–3 spinal sites (cervical/thoracic/lumbar; ECOG 0–2; no overlapping radiation, prior surgery at the site, myeloma/lymphoma, major neurologic deficits, or high SINS) are randomized to spine SRS delivered as 22 Gy × 1 versus 14 Gy × 2. The trial compares 1-year local control, safety, pain, vertebral fracture risk, and patient-reported outcomes between these standard SBRT regimens.

ClinicalTrials.gov ID: NCT06173401

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling children and adults with NTRK1/2/3 fusion–positive differentiated thyroid cancer (post-thyroidectomy) with CT-evaluable pulmonary metastases and no prior RAI or systemic therapy. Patients receive a 6-month lead-in of larotrectinib (selective TRKA/B/C inhibitor) followed by radioactive iodine (131I), aiming to enhance RAI avidity and induce complete pulmonary responses.

ClinicalTrials.gov ID: NCT05783323

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with high FRα expression (≥75% cells ≥2+ by VENTANA FOLR1), both platinum-sensitive and -resistant (not primary refractory), receive mirvetuximab soravtansine (FRα-targeted antibody–drug conjugate delivering DM4) IV q3w. Patients are randomized to ocular AE prophylaxis with prednisolone acetate eye drops vs brimonidine, with serial ophthalmic assessments; key exclusions include significant ocular disease, >Grade 1 neuropathy, prior FRα therapy, and poor baseline vision.

ClinicalTrials.gov ID: NCT06365853

Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with relapsed non-seminomatous germ-cell tumor (including ovarian GCT) who completed two tandem cycles of high-dose chemotherapy with peripheral-blood stem-cell transplant and have nonrising AFP/hCG are randomized to maintenance oral etoposide 50 mg daily versus observation. Etoposide is a cytotoxic topoisomerase II inhibitor used here as low-dose maintenance to reduce micrometastatic relapse risk.

ClinicalTrials.gov ID: NCT04804007

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral belzutifan, a selective HIF-2α inhibitor, for adults with recurrent or persistent clear cell ovarian carcinoma (≥50% clear cell if mixed) with measurable disease after at least one prior platinum regimen; prior bevacizumab and immunotherapy allowed and treated/stable brain metastases permitted. Patients receive daily belzutifan in 28-day cycles until progression/toxicity, with primary endpoints of ORR and 6-month PFS; class-toxicities include anemia and hypoxia.

ClinicalTrials.gov ID: NCT06677190

A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum‑resistant high‑grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (ECOG 0–1; prior bevacizumab required and PARP inhibitor if BRCA+) receive gemcitabine plus autologous memory‑like NK cell therapy (M‑CENK) with N‑803, an IL‑15 superagonist that expands NK and CD8 T cells. The regimen starts with gemcitabine, then adds repeated M‑CENK infusions and subcutaneous N‑803 from cycle 2 until cell product exhaustion or progression.

ClinicalTrials.gov ID: NCT06710288